Final Results

DawMed Systems PLC 05 December 2005 For immediate release 5 December 2005 DAWMED SYSTEMS PLC FINAL RESULTS FOR THE YEAR ENDED 30 SEPTEMBER 2005 The Board of DawMed Systems plc ('DawMed' or 'the Company'), the medical devices company, which designs, manufactures, sells and services washer disinfectors used by NHS Trust hospitals, private hospitals and clinics, today announces Final Results for the year ended 30 September 2005. Key Points: •Turnover up 30.7% to £6.16m (2004: £4.71m); •Gross profit up 41.5% to £2.54m (2004: £1.79m); •EBITDA at £264,800 up by £519,00 (2004: loss of £254,300); •Operating profit a t£75,600 up by £433,200 (2004: loss of £357,600); •Net profit after interest and taxation at £27,200 up by£430,300 (2004: net loss of £403,100); •Support Services division increases sales by 52.4%; •Shareholders' funds of £1,134,100 - an improvement of £289,700 over the previous year-end; •Successful development and introduction of the 'AERclens' Automatic Endoscope Reprocessor; and •Strong working capital position. No net debt at the year-end. Commenting on today's announcement, Kevin Gilmore, Executive Chairman of DawMed, said: 'Today's results have surpassed the Board's expectations indicated in my Interim Statement at the half year stage and fully reflect the cautious optimism expressed in my Statement in the Annual Report and Accounts for the previous year ended 30 September 2004. As the figures confirm, all sectors of the Company's business showed improvement over the previous year, further growth is anticipated in most of those sectors and, with the launch of three new products for shipment in this 2005/2006 financial year, one of which is aimed at what the Directors believe is a large and currently untapped market, I have a measured optimism for this year and for the longer term future of the Company.' --ENDS-- Enquiries: DawMed Systems plc Tel: 01789 740010 Kevin Gilmore, Executive Chairman Beaumont Cornish Limited Tel: 020 7628 3396 Roland Cornish Bishopsgate Communications Limited Tel: 020 7430 1600 Maxine Barnes / Nick Rome For further information please visit DawMed's website at www.dawmed.com Chairman's Statement I have pleasure in announcing that your Company has produced considerably improved results for the year ended 30th September 2005, which have surpassed the Board's expectations indicated in my Interim Statement at the half year stage and fully reflect the cautious optimism expressed in my Statement in the Annual Report and Accounts for the previous year ended 30 September 2004. Financials Turnover increased to £6.16m, an improvement of some 30.7% over the previous year's £4.71m. Significant growth was achieved in Support Services which increased sales by 52.4% over last year. Sales of large WDDs ('Washer-Disinfector-Dryer') machines to SSDs ('Sterile Services Department') almost doubled compared with the previous year largely as a result of the substantial contract for the supply and installation of Beta washer-disinfector-dryers (WDD's) to the Royal Victoria Hospital in Belfast. The supply on that contract is now complete. The overall sales of Wassenburg products were in line with last year and sales of the Clinic bench-top WDD, which were substantially improved over the previous year and increasing in the second half of the year, have begun to achieve volume expectations in the NHS Primary Healthcare sector and also in the private dental market. Sales of spare parts continued to remain buoyant with performance 16.1% ahead of last year. The overall sales improvement generated a gross profit of £2.54m, an increase of 41.5% over the previous year's £1.79m and the gross profit percentage increased by three percentage points. The main contributory factors giving rise to this increase were the excellent results produced by Support Services where the gross profits almost doubled compared with last year, the much improved volumes in the large SSD business resulting in usefully increased gross profits and the continuing good performance of the Wassenburg product group aided by its healthy chemical sales. Total overhead spend in the year of £2.47m was 14.5% up on the previous year's total of £2.15m. Operating overheads, before central costs, depreciation and amortisation, were 12.9% up on last year whilst central costs were reduced by 21.3%. Depreciation and amortisation charges increased by 96.1% as a direct consequence of a full year's amortisation charges on the Clinic R & D expenditure. The only significant increases in operating overheads occurred in Support Services and Clinic manufacturing, both as a result of increased business levels. Earnings after finance charges, but before interest, taxation, depreciation and amortisation ('EBITDA') were £264,800 compared with a first half result of £128,100, thus showing a slight increase in the second half. This performance is a substantial improvement over last year, which showed an EBITDA loss of £254,300, and represents an impressive turnaround of £519,100. Similarly, the operating profit before interest of £75,600 compares with an operating loss of £357,600 for the corresponding period last year, a substantial turnaround of £433,200. The net profit after interest and taxation was £27,200 for the year, against a net loss of £403,100 in the previous year, a notable turnaround of £430,300. The Balance Sheet showed shareholders' funds of £1,134,100 as at 30th September 2005, an improvement of £289,700 over the previous year-end. This resulted partially from the return to profitability in the year and partially from the proceeds of the share issue in January 2005. The working capital position also improved in the year with net current assets improving by £403,400 and net cash flow by £274,400. The company had no net debt at the year-end. Products and Services As the figures above confirm, all sectors of the Company's business showed improvement over the previous year, but none more so than the Support Services organisation. The Board's decision to allocate significant financial and human resources to this sector has been rewarded with excellent results and significant growth over the last three years. Further resources are being provided in the current year to ensure that this activity maintains its record as one of the growth sectors of the Company and that enhanced profitability continues to be achieved. The sales performance of the Wassenburg products was in line with the previous year and was augmented by the associated chemical sales and related Support Services. The sales performance of the SSD machines provided a welcome respite from the effects of the previous year's performance, but still remained a somewhat irregular and competitive market. It now seems clear that the Company was ahead of its time in identifying the need and opportunity for equipment for the decontamination of surgical instruments in Primary Healthcare to introduce the prevention of cross infection from one patient to another during minor surgical procedures. The Company's 'Clinic' bench top WDD broke new ground in its design and development from scratch of a miniature version of its large hospital type WDD, incorporating all of its technical features including full compliance with current and imminent standards. Following the slow start to Clinic sales that perhaps all pioneers suffer, I am now pleased to report that the Company has been successful in significantly increasing the English and Welsh NHS Primary Healthcare sector and private dental sector awareness with consequential improved sales. Outlook and Future Prospects Whilst the supply of large WDD machines to SSD's (Sterile Services Departments) of NHS and Private Secondary Healthcare hospitals was favourably affected in the year by some satisfactory contracts, this element is still undergoing the careful monitoring, referred to in my previous Annual Report Statement, of the high working capital requirement, the cyclical nature of demand and diminishing margins in a fiercely competitive field. The Wassenburg opportunities are expected to continue to expand, particularly with the launch of two new products for shipment during the 2005/2006 financial year, viz. the state-of-the-art flexible endoscope drying and storage cabinets and the 'pass-through' flexible endoscope WD. The new pass-through machine is expected to be delivered into the UK market during the current 2005/2006 year and promises to be an exciting addition to the existing product range to complement the original against-the-wall space saving machine. Similarly, the entirely new product range of Wassenburg drying/storage cabinets offers technically advanced products for use in all Private and NHS hospital departments using flexible endoscopes, irrespective of the type of WD in use, provides economic advantages to such departments and complements the extended range of Wassenburg flexible endoscope WD's. I am pleased to announce their introduction into the UK market and look forward with enthusiasm to these new products opening up new sales opportunities for the Company in the second half of this year. Following the Clinic's success in the English NHS Primary Healthcare sector and in the private dental sector in England and Wales, further success is anticipated as a result of the Clinic's inclusion on the Scottish Health Service ('SHS') preferred supplier list and a groundswell of increased awareness and interest from the important private dental sector across the UK and the Republic of Ireland. In Scotland, new decontamination guidelines for the predominantly SHS dentists have been issued, underpinned by substantial funding to assist the dentists to purchase compliant decontamination equipment. The Company is taking positive action to ensure that it captures a meaningful share of this market, ably supported by its Scottish distributor. The Board firmly believes that the combination of the Department of Health's directive for all Primary Healthcare practitioners to be equipped with fully compliant decontamination equipment by the end of March 2007 and the increased awareness of the need for automatic washing, disinfecting and drying instruments in the Private, NHS and SHS Primary Healthcare sector, will augur well for the Company's Clinic sales performance in the current year. Support Services goes from strength to strength and the near doubling of the gross profit contribution from this organisation speaks for itself. It is anticipated that further growth will be achieved in the current year, including expansion of the Training function and the possible establishment of additional service functions during the current year. Notwithstanding my concluding comments a year ago, and following the Company's successful entry into, and subsequent capture of a predominant share of the WD market for the decontamination of large flexible endoscopes, the Company has used its not inconsiderable expertise to design, develop and 'productionise' a new bench top Washer-Disinfector for an entirely new, and in the Directors' opinion untapped market, viz. the decontamination of small flexible fibre optic laryngoscopes (also known as nasendoscopes) which do not have suction or instrument channels and are used as diagnostic tools in ENT ('Ear, Nose and Throat') departments of NHS and Private Secondary Healthcare hospitals and private Consulting Rooms for the examination of nasal cavities, pharynx and larynx. This AER ('Automatic Endoscope Reprocessor') machine is aimed at departments and consulting rooms that currently use only manual, labour-intensive methods of washing and disinfection. The Company's innovative 'AERclens' WD machine will offer a fully compliant automatic, efficient, controlled and cost-effective solution to users that hitherto have only been able to use the inadequate and non-validated manual methods. The Company plans to commence sales of the 'AERclens' machine and its related accessories and chemicals in the second half of the current financial year, following its recent successful launch at both domestic and international exhibitions. The Board intends to pursue vigorously this truly exciting opportunity and provide the resources to maximise the potential in the UK and Europe, perhaps leading to worldwide potential in due course. No shareholder will be surprised to hear that a great deal of hard work and dedication has gone into the achievement of these improved results and the laying of foundations for hopefully future benefits. On behalf of the Board I am pleased to thank and congratulate all our employees for their vital contributions. I commend this Report and Accounts to all shareholders and trust that the Directors' commitment to its contents and their measured optimism for the current year and for the longer term future of your Company will be acknowledged and shared respectively by existing and new shareholders. Enquiries: DawMed Systems plc Kevin Gilmore, Executive Chairman Tel: 01789 740010 Beamont Cornish Limited Roland Cornish, Executive Chairman Tel: 020 7628 3396 Bishopsgate Communications Limited Dominic Barretto/Maxine Barnes Tel: 020 7430 1600 Dawmed Systems plc 2005 2004 CONSOLIDATED PROFIT AND LOSS ACCOUNT £ £ for the year ended 30 September 2005 TURNOVER 6,158,223 4,713,357 Cost of sales (3,616,602) (2,917,212) Gross profit 2,541,621 1,796,145 Administrative expenses (2,466,066) (2,153,695) OPERATING PROFIT/(LOSS) 75,555 (357,550) Interest receivable and similar income 10,292 8,701 Interest payable and similar charges (58,619) (54,315) PROFIT/(LOSS) ON ORDINARY ACTIVITIES BEFORE TAXATION 27,228 (403,164) Taxation - - PROFIT/(LOSS) FOR THE YEAR 27,228 (403,164) EARNINGS/(LOSS) PER SHARE 0.14p (2.24)p DILUTED EARNINGS/(LOSS) PER SHARE 0.14p (2.24)p Dawmed Systems plc 2005 2004 CONSOLIDATED BALANCE SHEET £ £ 30 September 2005 FIXED ASSETS Intangible assets 485,501 641,966 Tangible assets 65,907 66,424 551,408 708,390 CURRENT ASSETS Stocks 506,164 514,036 Debtors 1,387,702 1,355,383 Cash at bank and in hand 601,071 326,628 2,494,937 2,196,047 CREDITORS: Amounts falling due within one year (1,845,703) (1,950,258) NET CURRENT ASSETS 649,234 245,789 TOTAL ASSETS LESS CURRENT LIABILITIES 1,200,642 954,179 CREDITORS: Amounts falling due after more than one year (66,554) (109,846) NET ASSETS 1,134,088 844,333 Called up share capital 1,023,165 923,165 Share premium account 1,872,239 1,709,712 Merger reserve (350,520) (350,520) Profit and loss account (1,410,796) (1,438,024) SHAREHOLDERS' FUNDS 1,134,088 844,333 Dawmed Systems plc 2005 2004 CONSOLIDATED CASHFLOW STATEMENT for the year ended 30 September 2005 £ £ Net cash inflow/(outflow) from operating activities 396,157 (380,064) Returns on investments and servicing of finance Interest received 10,292 8,701 Interest paid (58,619) (54,315) (48,327) (45,614) Capital expenditure and financial investment Purchase of fixed assets (69,413) (183,288) Receipts from sale of fixed assets 600 - (68,813) (183,288) Financing Issue of ordinary shares 262,527 513,400 Factoring and stock advances (254,929) 219,787 Finance leases (12,172) 26,880 (4,574) 760,067 Increase in cash 274,443 151,101 Reconciliation of operating profit/(loss) to net cash inflow/(outflow) from operating activities Operating profit/(loss) 75,555 (357,550) Depreciation and amortisation charges 225,795 123,720 Movement in stocks 7,872 (39,542) Movement in debtors (32,319) (178,242) Movement in creditors 119,254 71,550 Net cash inflow/(outflow) from operating activities 396,157 (380,064) Notes 1. The calculation of earnings per share is based upon the profit after taxation of £27,228 (2004 loss: £403,164) and on 19,909,867 shares (2004: 17,991,160 shares) being the weighted average number of ordinary shares in issue during the year. Since the exercise price of the 2,236,676 (2004: 2,236,676) share options is above the average fair price for the year and the prior year, the diluted earnings per share is equivalent to the basic earnings per share. 2. The Consolidated Profit and Loss Account and Balance Sheet information for the years ended 30 September 2005 and 30 September 2004 shown above has been extracted from the Statutory Accounts for those years on which the auditors gave an unqualified opinion. Statutory Accounts for the year ended 30 September 2004 have been delivered to the Registrar of Companies. The Statutory Accounts for the year ended 30 September 2005 are due to be delivered to the Registrar following conclusion of the forthcoming Annual General Meeting. A copy of this statement is available from the offices of Beaumont Cornish Limited, 5th Floor, 10-12 Copthall Avenue, London, EC21 7DE This information is provided by RNS The company news service from the London Stock Exchange

Companies

Adams (ADA)
UK 100

Latest directors dealings